[ad_1]
Novo Nordisk A/S (NYSE:NVO) is included in our checklist of the 13 Greatest Extraordinarily Worthwhile Shares to Spend money on Now.
In line with a January 28, 2026, Reuters report, Novo Nordisk A/S (NYSE:NVO) elevated its promoting spending for its GLP-1 treatment within the U.S. Within the first 9 months of 2025, the corporate allotted almost $500 million to advertise Wegovy and Ozempic. The allotted funds is greater than twice Eli Lilly’s spending on rival therapies.
As provide constraints eased and aggressive pressures elevated, Novo spent $316 million on Wegovy and $169 million on Ozempic, in line with MediaRadar. This highlights year-over-year will increase of 54% and 44%, respectively.
The elevated promoting displays Novo’s efforts to defend its market place after Eli Lilly’s Zepbound showcased better weight-loss efficacy in late 2024 trial information, surpassing Wegovy in U.S. prescription quantity. Novo’s administration additionally plans to right away promote its upcoming oral model of Wegovy and increase distribution by means of cash-pay and direct-to-consumer channels.
On the prior day, Citi initiated protection of Novo Nordisk A/S (NYSE:NVO) with a ‘Impartial’ score and a DKK 400 worth goal, noting that the corporate’s valuation seems truthful at present ranges regardless of continued excessive demand for weight problems therapies.
Novo Nordisk A/S (NYSE:NVO), a worldwide pharmaceutical firm, makes a speciality of treating uncommon ailments, diabetes, and weight problems.
Whereas we acknowledge the potential of NVO as an funding, we consider sure AI shares provide better upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on one of the best short-term AI inventory.
READ NEXT: What Are the Greatest Shares to Purchase Proper Now? and 10 Shares Beneath $1 That Will Explode.
Disclosure: None.
[ad_2]
